Natures Sunshine Products INC

Natures Sunshine Products, Inc. announced the resignation of its CFO, L. Shane Jones, effective June 5, 2026, and the appointment of Jonathan D. Lanoy as interim Principal Financial Officer.

Nature's Sunshine reported a 9% increase in Q1 2026 net sales to $122.9 million and received shareholder approval for its 2026 Stock Incentive Plan.

Natures Sunshine Products reports strong third-quarter 2025 financial results with net sales up 12% to $128.3 million and a raised full-year outlook.

Natures Sunshine Products, Inc. announced the appointment of Kenneth Romanzi as its new Chief Executive Officer, succeeding Terrence O. Moorehead, effective October 29, 2025.

Nature's Sunshine Products, Inc. announced robust second-quarter 2025 financial results, featuring increased net sales and adjusted EBITDA, leading to an upward revision of its full-year guidance.

Nature's Sunshine Products, Inc. will acquire the remaining 20% interests in its Hong Kong and Shanghai joint ventures from Fosun Industrial for a total of $7 million in cash, following Fosun Pharma's reduction in its stake in Nature's Sunshine.

Nature's Sunshine Products reported an 8.5% increase in Q1 2026 net sales to $122.9 million, driven by growth across all geographic segments.

Natures Sunshine Products, Inc. announced significant increases in net sales and net income for the third quarter and first nine months of 2025, alongside the appointment of Kenneth G. Romanzi as its new Chief Executive Officer.

Nature's Sunshine Products, Inc. announced a significant increase in net income and earnings per share for the second quarter and first half of 2025, driven by sales growth, improved gross margins, and favorable foreign exchange dynamics, alongside a strategic move to acquire full ownership of its China joint ventures.

Natures Sunshine Products saw a 2.0% increase in consolidated net sales for Q1 2025, driven by growth in Asia and Europe, despite headwinds from foreign exchange rates.

Natures Sunshine Products saw a slight increase in net sales in Q3 2024, but faced challenges from inflation and currency fluctuations.

Natures Sunshine Products experienced a 5.1% decrease in consolidated net sales for the second quarter of 2024, while managing to increase operating income.

Natures Sunshine Products experienced a slight increase in consolidated net sales for 2024, but faces ongoing challenges including regulatory scrutiny and global economic pressures.

Natures Sunshine Products Inc. reports a 5.5% increase in consolidated net sales for 2023, alongside identifying a material weakness in internal controls related to unauthorized wire transfers.

Kevin R. Herbert, EVP & President, North America for Nature's Sunshine Products Inc., reported a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

EVP and President of North America Kevin R. Herbert sold 2,000 shares of Nature's Sunshine Products, Inc. (NATR) on June 12, 2026.

Bryant J. Yates, EVP & President of Europe at Nature's Sunshine Products, sold 11,968 shares of common stock.

Daniel C. Norman, EVP & President of Asia at Nature's Sunshine Products, sold 9,713 common shares at $20.64 per share.

EVP and General Counsel Nathan G. Brower sold 12,015 shares of Nature's Sunshine Products, Inc. at an average price of $21.84.

Steven J. Fasching, a Director at Natures Sunshine Products Inc., reported the acquisition of 4,500 common shares through restricted stock units.

Nature's Sunshine Products, Inc. announces its 2026 Annual Meeting of Shareholders to address director elections, executive compensation, auditor ratification, and a new stock incentive plan.

Nature's Sunshine Products will hold its 2025 Annual Meeting of Shareholders on April 30, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

A preliminary proxy statement has been filed, indicating upcoming corporate actions requiring shareholder votes.

Nature's Sunshine Products, Inc. has released its definitive proxy statement, outlining proposals for the upcoming 2024 Annual Meeting of Shareholders, including the election of directors, executive compensation, and ratification of the company's accounting firm.

Fosun Pharma USA Inc. has completed the sale of over 2.8 million shares of Nature's Sunshine Products Inc. common stock, reducing its beneficial ownership to below 5%.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has transferred 2,854,607 shares of Nature's Sunshine Products, Inc. common stock to its wholly-owned U.S. subsidiary, Fosun Pharma USA Inc., as disclosed in an amended Schedule 13D filing.

BlackRock, Inc. has reported beneficial ownership of 5.04% of Nature's Sunshine Products, Inc. common stock as of September 30, 2025.

Dimensional Fund Advisors LP has reported a 5.2% beneficial ownership stake in Nature's Sunshine Products Inc., held for investment advisory purposes.